This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Tuesday, November 11, 2014
AASLD Conference Reports: HCV Data, slide presentations categorized by genotype and pharmaceutical company
65th Annual Meeting of the American Association for the Study of Liver Diseases
Comprehensive data investigating HCV interferon-free, ribavirin-free regimens presented at the liver meeting is now available on the website.
Updated daily, categorized by genotype and pharmaceutical company, with links to breaking news, clinical data, commentary and slide-sets from premier Hepatitis C websites.
Hepatitis C New Drug Research: Conference Reports
No comments:
Post a Comment